calm before the ???, page-9

The post is based on my discussions with the company. My understanding of the unblinding of the 24 week data is that the FDA will advise in Feb the requirements to take ATC forward. That could for example be a partial or limited approval with ongoing testing. This will provide potential partners with the information they need to make a commercial decision.